Study of surface electrocardiogram spectrum before and after pulmonary vein ablation in patients with persistent atrial fibrillation.
Atrial fibrillation (AF) is the most common clinical cardiac arrhythmia and is usually treated with the electrical isolation of the pulmonary veins from the atria. However, it is estimated that about 30% of the patients undergoing this therapy will develop AF again. The purpose of this study was to test the dynamic changes of the spectra calculated in surface electrocardiograms (ECGs) before and after the ablation of the pulmonary veins. Surface ECGs of 14 patients with persistent AF undergoing this intervention were considered for this study. The QRS-T waves were subtracted from the ECGs using common spatial pattern, isolating the electrical activity of the atrium. The spectrum was then calculated and the main frequency peaks were identified. The smaller peaks with amplitude below 50% of the maximum were discarded. Eleven of the patients were followed up after the intervention for 1 to 6 months. Two of the patients developed AF again; the other 9 remained in sinus rhythm. For most of the patients, the spectrum showed more order after the intervention. However, the main frequency did not experience a significant decrease in average (5.1 Hz [+/-1.3] to 4.9 Hz [+/-1.0]). Interestingly, the increment or decrease of the main frequency did not correlate with the recurrence of AF or not.
Romero
Iñaki
I
Physikalisch Technische Bundesanstalt, Berlin, Germany. inaki@napier.ac.uk
Koch
Hans
H
Fleck
Eckhart
E
Kriatselis
Charalampos
C
D001281:Atrial Fibrillation / Q000175:diagnosis* / Q000601:surgery*; D017115:Catheter Ablation; D003936:Diagnosis, Computer-Assisted / Q000379:methods*; D004562:Electrocardiography / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011182:Postoperative Care / Q000379:methods; D011300:Preoperative Care / Q000379:methods; D011379:Prognosis; D011667:Pulmonary Veins / Q000601:surgery*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D016896:Treatment Outcome